Q4 2024 Adaptimmune Therapeutics PLC Earnings Call
Speaker Change: Hello, and welcome to the Adaptimmune Q4 and full-year 2024 Business Update conference call. As a reminder, all participants are in a listen-only mode, the conference is being recorded.
Speaker Change: After the presentation, there will be an opportunity to ask questions. To join the question, can you may press star and then one on a telephone keypad? Should you need assistance during the conference call? You may signal the operator by pressing star and zero.
Speaker Change: We now like to turn the floor over to Juli Miller. Invest the relations for Adaptimmune. Juli, please go ahead.
Juli Miller: Good morning and welcome to Adapt Immune's conference call to discuss our full year and fourth quarter 2024 business updates.
Juli Miller: We anticipate making projections during this call an actual result could differ materially due to several factors, including those outlined in our latest filings with the SEC.
Speaker Change: Thanks, Juli, and thank you everybody for joining us on today's call.
Speaker Change: I'd like to begin by discussing the TSELRA launch and the fantastic momentum that we've seen building since our approval late last year.
Speaker Change: This launch as you know has been our top priority and we have provided some updated performance metrics.
in this morning's press release.
Speaker Change: But I'm going to go into more details on this call so that you can see why we're so excited that our long-range forecast of at least $400 million in combined synovial sarcoma sales seems very achievable given these early success indicators.
Speaker Change: These 20 ADCs represent a full two-thirds of our plan treatment network of approximately 30 sites. So we are very much ahead of schedule in setting up these ADCs.
Speaker Change: When we launched last year, we intended to have the full network established by late 2026 and our Q3 earnings in November and based on enthusiasm from sites and the progress that we're seeing up to that point, we accelerated that timeline to the end of this year. [inaudible]
Speaker Change: Now, having two-thirds of these sites up and running already, we are very much on track to have the full network by the end of the year.
Speaker Change: Now on to patients being treated with T-Sour. In Q4 last year, we aphorised three patients and two of those were invoiced, resulting in Q4 recorded product revenue of $1.2 million.
Speaker Change: In Q1 2025, as of today, we have Aferiste 10 more patients and we have three additional Aferistes scheduled by the end of March for an anticipated total of 13 patients Aferiste in Q1 2025.
Speaker Change: This means we're likely to afer each more than four times as many patients in Q1 as we did in the prior quarter. [inaudible]
Speaker Change: Furthermore, we anticipate that the majority of the 10 patients they've reached in Q1 to date will be invoicing Q1 with a remainder in Q2. Now, as such, we anticipate invoicing three to four times as many patients in Q1, i.e. approximately six to eight patients as we did in the prior quarter.
Speaker Change: We can see this launch is accelerating rapidly, and our KPIs are in line with or indeed exceeding our projections, which is a testament to the team's hard work and to the unmet need of sarcoma patients and the recognition from their treating physicians that Tisawa offers a real solution.
And we anticipate the acceleration of these numbers will continue.
Speaker Change: We have an additional pool of around 20 patients who are biomarker positive and we expect the majority of these patients to be treated in Q2 and Q3 this year and behind that we estimate that approximately 30 patients are in various stages of testing.
Speaker Change: Now, we don't have full visibility in all of the major A4 testing that occurs, but more than 80 patients have completed testing for major A4 using our sponsored testing programs since launch, with a positivity rate, which has expected around 65%.
On the payer front, we've had tremendous success with reimbursement. [inaudible]
Speaker Change: Over 70% of commercial and Medicare lives are in plans that already have established policies in place to cover T-Sour. To date, we haven't experienced a single denial, which is a great accomplishment for the team and even greater outcome for patients obviously. Thank you very much.
Speaker Change: Before we remove of Lord's performance, I'll be remiss not to discuss manufacturing. Thank you very much.
Speaker Change: Since this is so important for South therapies, as you know, an effective, efficient delivery of ontologist-self therapies is in our view a critical, indeed a defining characteristic, the successful commercialization campaigns.
Speaker Change: The several manufacturing has exceeded all of our goals and expectations. Although the numbers so far are small, 100% of the released products were manufactured to specification with no manufacturing failures.
Speaker Change: Our average turnaround time from aporesis to product release has been less than our target at 30 days. We've had no capacity bottlenecks so far, and we have a robust supply of all the key materials, including importantly vector already in place.
Speaker Change: We should have no trouble meeting that anticipated accelerating demand in the coming quarters that I referenced earlier.
Speaker Change: The net results of everything we're seeing across our treatment network are commercial and manufacturing teams.
Speaker Change: is that we anticipate sales of T-cellera will continue to accelerate in each quarter this year as the pipeline of new patients flows through as new ATCs come online and as the timelines for each patient moving through the process becomes more efficient and more streamlined. Thank you very much.
Speaker Change: As of now, we have good visibility of the patients we expect for delivery in April . And although we're not yet in a position to provide formal revenue gains, we feel very confident that the current consensus analyst forecast of approximately $25 million of sales in 2025 is very achievable.
Speaker Change: This is a testament to the commercial and CMC capabilities we've thoughtfully and strategically built and which are now firing on all cylinders.
Speaker Change: Most importantly though, it's a testament to the strength of the clinical data, as reflected in the approved label, which has provided patients and their treating oncologists with the confidence that decelerates the right choice. Thank you.
Speaker Change: Now we've built this commercial infrastructure in the name of Tissera, the first product in the psychoma franchise, but also for the next product, let us out, which we expect to be on the market in 2027.
Speaker Change: The data we've generated for let us all is as strong as that for Tissera and will be in basis for the BLA filing which is on track for submission later this year.
Speaker Change: Tisura and let us out form the basis of our Sarkoma franchise, and…
Speaker Change: As stated previously, we expect to see US peak sales of approximately $400 million.
Speaker Change: Since let us know, we will use the same commercial footprint as T-cellera. We will achieve significant operational, channel and cost synergies. Put another way.
Speaker Change: The incremental cost to launch letters that live minor given that most of the capabilities will already be in place by the time of launch in 2027.
Speaker Change: Now I'm going to elaborate a little more on Letticell and in particular on the Ignite ESO pivotal data that met its primary endpoint and was presented at CETOS last year.
Speaker Change: So to the Angela who has been the lead investigator in our trials framed let yourself from the perspective of the provider. She was enthusiastic not only about the data, but also about having another feature treatment option.
Speaker Change: She speaks compelling day about how patients who often in the prime of their lives receive a devastating diagnosis of synovial sarcoma or myxoid life of sarcoma and have limited treatment options.
Speaker Change: At the end as I've highlighted let yourself significant improvement over standard of care and described the treatment journey from screening to dosing is streamlined.
Speaker Change: Want to understand the transformative nature of these therapies in this space I encourage you to listen to our presentation, which is on our website.
Speaker Change: Let's just say, we will expand our cloud coma franchise into NY ESO expressing synovial sarcoma myxoid life of sarcoma, which we anticipate will more than double the number of treatable patients in the U S. Each year.
Speaker Change: We estimate the letters that will eventually make up over 60% of our combined Sakai of a franchise revenue.
Speaker Change: Switching gears, a little last quarter, we shared the key priorities for our restructuring and for the company going forward.
These were one to build a successful business with what we anticipate will be two FDA approved products in sarcoma.
Speaker Change: Two to substantially reduce the need to bring in additional capital before becoming cash flow positive and.
Speaker Change: And three to achieve our objective to be cash flow breakeven in 2027.
Speaker Change: The update of the launch of <unk> and the progress with let yourself demonstrates we are well on track to meet the first of these objectives building all sarcoma business.
Speaker Change: While the capital reductions in the cash flow breakeven in 2027 objectives, we have two updates for you today.
Speaker Change: First we are pausing spending on our preclinical programs targeting frame and CD 70.
Speaker Change: This decision reduces our forward cash flow demands in the period through 2028 by approximately $75 million to $100 million.
Speaker Change: This is in addition to the $300 million of full cash savings over this period, we announced at the end of last year as a result of our restructuring.
Speaker Change: Secondly, we've engaged TD Cowen to help us explore all strategic options and evaluate every financial opportunity to ensure we achieve our goals and optimize value for our shareholders.
Speaker Change: This includes potential partnerships or collaborations strategic combinations various financial transactions on multiple pipeline monetization opportunities.
Speaker Change: We won't say much more beyond this and while we appreciate all your questions. We will only provide an update on the progress of these initiatives when we have something meaningful to discuss.
Speaker Change: We have a lot of options of financial levers, we can pull while we continued to execute our commercial strategy.
Speaker Change: This unit of strength with the early success of the T cell alone.
Speaker Change: In summary, we have great traction and acceleration of the launch of T cell and we will continue to provide updates on this and the progress of letters out towards a rolling BLA submission later this year.
Speaker Change: We will continue to effectively manage our costs as we push towards profitability in 2027 and in the context of the current capital markets. We will leave no stone unturned to enable us to achieve our objectives.
Speaker Change: With that I'll open the call up for questions operator.
Speaker Change: And ladies and gentlemen at this time, we'll begin the question and answer session.
Speaker Change: Joining the question queue, you May press Star and then one on your telephone keypads, you'll hear a tone acknowledging your request.
Speaker Change: If you are using a speaker phone, we do ask that you. Please pick up your handset prior to pressing the keys.
Speaker Change: Withdraw your question you May press Star two.
Speaker Change: We will pause a moment as callers join the question queue.
Speaker Change: Our first question today comes from.
Speaker Change: Mark from from TD Cowen. Please go ahead with your question.
Speaker Change: Hi, This is Alex on for Mark. Thanks, So much for taking my question just a couple of them that the seller of launch. So first could you comment on the pace of that for instance, during Q1, specifically where patient numbers higher in March versus January.
Speaker Change: And then given the cost savings you're working on how many patients per year do you think you'll need to treat in order to achieve profitability in 2027.
Speaker Change: So I'm going to ask Cynthia to comment on the pace of eight races. As we've gone through the last part of last year and into this year.
Speaker Change: And then I'll I'll take the second question on profitability for the company as a whole.
Cynthia: Thank you Adrienne. Thank you so much so yes, the pace of the phases has been increasing as you would imagine we added to open our HFC network and last year. So the majority of the air.
Cynthia: So you just came from the first agencies that were open we see that.
Cynthia: It should be.
Cynthia: Five different agencies and as we continue to on board a tree.
<unk> centers that base has been increasing over time, so we certainly had a greater number.
Cynthia: Freezing in February and March than we had in the prior months.
Cynthia: The base has been really very exciting.
Cynthia: On the on the second question.
Cynthia: <unk>.
Cynthia: Deliberately and specifically haven't provided forward revenue guidance.
Cynthia: Through any of the mechanisms that are your questions imply I'm, sorry, I'm not going to I'm not going to actually give you broad guidance on 2027 at that point, but other than to say that the by that point of course.
Cynthia: So that's a sort of it it's essentially in its second full year of launches third year after after approval.
Cynthia: And obviously lead to cell will have launched by that point in time. It is the combination of those two together.
Cynthia: Get us to operating profitability.
Cynthia: Great. Thank you.
Cynthia: Yes, Alex.
Speaker Change: Our next question comes from Michael Schmidt from Guggenheim. Please go ahead with your question.
Speaker Change: Hi, This is Paul on for Michael Thanks for taking my questions.
Speaker Change: So just on the watch us well last quarter I believe you mentioned that had been 15 confirm double positive patients as of November can you just confirm what proportion of those patients are the ones who went on to undergo embraces this year and for those who did not are they still candidates for treatment down the line or if they dropped out of the treatment journey do you have any visibility into why.
Speaker Change: Yeah.
Speaker Change: The zip.
Speaker Change: Yes, so we need the majority of the patients that were double positive has already been.
Speaker Change: Starting the journey and the 10 patients directly a freeze so far are part of those.
Speaker Change: A majority of the other is there a skew in the journey at different stages.
Speaker Change: Would expect some dropouts not all of the patients are going to eventually be treated.
Speaker Change: We haven't seen a lot of them to be but there could be different reasons why patients could potentially drop out, but what we see.
Speaker Change: The majority of them went away freezes are ours to waiting to be treated.
Speaker Change: Okay.
Speaker Change: And then perhaps just a follow up.
Speaker Change: Do you have any visibility into what line of therapy. The patients typically are on who are going into testing in other words, what proportion of patients who are getting tested could immediately move into treatment of qualified as double positive versus those that are perhaps earlier and being tested in frontline and still being treated with other therapies. Thank you.
Speaker Change: The majority of the patients and the large majority of the patients are patients that are being tested with incomes to be treated with <unk>. So they have already been exposed to chemotherapy they could be in different stages of their journey.
Speaker Change: Overtime, we do expect to see testing happening.
Speaker Change: Here in the treatment journey, and it's something that we'll hopefully be able to support as we.
Speaker Change: You know grow into that the awareness of biomarkers that should be there.
Speaker Change: The majority of the patients tested.
Speaker Change: Ah patients that are eligible to start being discounted by the way.
Speaker Change: Okay. Thank you.
Speaker Change: Thanks, Bob.
Speaker Change: Our next question comes from Jonathan Chang from Leerink Partners. Please go ahead with your question.
Jonathan Chang: Hi, guys. Good morning, Thanks for taking my questions.
Jonathan Chang: First on the path to profitability in 2027, K mind us what what the assumptions are and other considerations that feed into that call.
Jonathan Chang: Suddenly so.
Jonathan Chang: When we were previous when we previously announced the restructuring we talked about the passion of our spending.
Jonathan Chang: In 2020 by 2026 and 2027 you.
Jonathan Chang: You might recall that we said that we would reduce our spending by about 50 million in anticipated in 2025 from the levels in 2024.
Jonathan Chang: And then by 70 to 80 million in each of 2026 and 2027.
Jonathan Chang: That implies a cost base coming down from a little north of 200 million to sort of $130 million to $140 million.
Jonathan Chang: We have now subsequently announced that we are pausing the investment in prime and $5 20, and whilst we haven't calendarize that that has a significant incremental impact in the in future years.
Jonathan Chang: On that reducing that still further.
Against that backdrop.
Jonathan Chang: Dropped we have the approval.
Jonathan Chang: The launch of the approval and launch of <unk>.
Jonathan Chang: Two products to several obviously last year in the sales of that which we are now really starting to see.
Jonathan Chang: Ramp up and offset that.
Jonathan Chang: And then we.
Jonathan Chang: We anticipate the approval of left to sell on the basis of the BLA, which will complete in the second quarter of next year, and which we anticipate the first sales in 2027.
Jonathan Chang: All up on approval in late 2026.
Jonathan Chang: Recognize sales in 2027, and it's the combination of those two ramping up we have not provided specific annual sales guidance for either product or in total, but we have said that we anticipate U S sales of <unk>.
Jonathan Chang: All.
Jonathan Chang: $400 million in total peak full for a soft guide of our franchise.
Jonathan Chang: Sure.
Jonathan Chang: Hopefully that's helpful.
Jonathan Chang: Understood. So so I guess just synthesizing all of that together did you believe you have sufficient cash.
Jonathan Chang: Today.
Jonathan Chang: To get to your goal of being profitable in 2027.
Jonathan Chang: Or does that assume does.
Jonathan Chang: Doug.
Jonathan Chang: We said that last year that remains the case now.
Jonathan Chang: And the opportunities that we are exploring with our with the help of TD Cowen.
Jonathan Chang: To enable us to bridge to that profitability.
Jonathan Chang: Two.
Jonathan Chang: Ensure that we are able to appropriately finance.
Jonathan Chang: Company.
Jonathan Chang: Over this time period to get to that goal of profitability in 2027.
Jonathan Chang: Understood maybe just one last question for me then how how are you guys thinking about potential business development opportunities for the company.
Jonathan Chang: We have programs platform et cetera.
Jonathan Chang: So we have we have.
We have a pipeline of.
Jonathan Chang: Of opportunities Craig C C.
Jonathan Chang: <unk> 70 program, we have an ongoing collaboration and partnership with our partner Galapagos or use a cell.
Jonathan Chang: And then we have the note in the U S.
Territories for sarcoma franchise, all of those are available for partnering.
Jonathan Chang: And as we said, we said last year that we were actively exploring and we continue to actively explore partnerships for all of those.
Jonathan Chang: More broadly we anticipate that.
Jonathan Chang: We'll explore all options to be able to see.
Jonathan Chang: Few of the future of the sarcoma franchises of the company.
Jonathan Chang: And just yeah, we anticipate that.
Jonathan Chang: Yes.
Jonathan Chang: Properly Finance company is our number one priority as you've seen the equity capital markets.
Jonathan Chang: <unk> now the good news is that T cell, where it's going as well if not better than we had the ambition, but that just makes it even more important to have a properly finance company.
Jonathan Chang: We are exploring all options that this includes the partnerships that you've mentioned and collaborations and includes strategic combinations that includes other financial transactions and the opportunity to monetize parts of our pipeline as well. So there's a lot of different levers that we are going to explore that.
Jonathan Chang: We're exploring in order to ensure that we can bridge through to that successful sarcoma franchise.
Jonathan Chang: Got it thanks for taking my questions.
Jonathan Chang: Thanks, Jonathan.
Speaker Change: Our next question comes from Tony Butler from Rodman and Renshaw. Please go ahead with your question.
Speaker Change: Good morning Adrian.
Speaker Change: Probably a question for you if you actually look at the show or map in realizing that.
Speaker Change: Golar 30, ATC site, obviously all of them to date or in the east in itself.
Speaker Change: West.
Speaker Change: The question is would the remainder of course very soon be in the Midwest.
Speaker Change: Missouri through I guess, you talk if you think about it but.
Speaker Change: But also importantly, given the cost comments that you've made cost reduction comments that you made.
Speaker Change: Is there a notion or a fault that you in fact may need more salespeople.
Speaker Change: Certainly in that Midwest region, Thanks, very much.
Speaker Change: Yes.
Speaker Change: I cannot just directly so thank you Tony yes. So.
Speaker Change: Yes, but the distribution of the site, whereas designed based on the concentration of patients that we see in the Pea.
Speaker Change: Cancer centers already so we do expect to see more in the middle of the country.
Speaker Change: But also the largest concentration and thats why a lot of the sites.
Speaker Change: Where they are today that the.
Speaker Change: A high concentration of patients that you would go with the pretty treatment centers is to be able to provide access.
Speaker Change: Their way to the majority of the patients.
Speaker Change: We currently have a footprint that we announced in before of HIFU engine with five key commercial needs and far as medically.
Speaker Change: Good.
Speaker Change: And we are open to exploring opportunities to continue to increase but at this point is still there.
Speaker Change: The right number of people that you need to provide the right focus on the treatment for Nash.
Speaker Change: Thanks Cynthia.
Speaker Change: Okay.
Speaker Change: Our next question comes from Greg <unk> from Mizuho. Please go ahead with your question.
Yeah. Thanks, Good morning, and thank you for the updates on launch and congrats there.
Speaker Change: Had two questions relatively brief can you just remind us about the commercial strategy as it currently right now where your energies are primarily are singularly focused on the U S or in other words can you just remind us what the ex U S.
Speaker Change: Strategy is that you would think that you would undertake on your own or is it with a partner.
Speaker Change: And then any.
Speaker Change: Timelines on filing in Europe, and then secondly, I was just struck.
Speaker Change: Just in the press release just on.
Speaker Change: I guess, the lack of the financials for the quarter I realize that the K.
Speaker Change: Might come out next week, but that being said any comments on opex in particular.
Speaker Change: And kind of thoughts around opex trends for 2025 given.
Speaker Change: The restructuring given the goal of achieving profitability in 2027 relative to the uptake for.
Sarah: Sarah Thanks.
Sarah: Thanks, Greg.
Speaker Change: I'll take the first question on broader strategies that commercials commercialization strategies on a soft kind of a franchise and then I'll ask Kevin to comment on the on the costs and the financials.
Sarah: So with respect to the.
Speaker Change: The ex U S.
Speaker Change: Our view is that.
Speaker Change: It is absolutely absolutely critical thing for us to do is establish a commercially viable.
Speaker Change: This around our sarcoma franchise in the United States and Thats the number one priority for us.
Speaker Change: From a product commercialization perspective.
Speaker Change: It is obvious to us that there is demand.
Speaker Change: Outside of the United States.
Speaker Change: And many people with synovial sarcoma, and Myxoid life of sarcoma, who would benefit from.
Speaker Change: T cell from let yourself.
Speaker Change: We've been clear for a while that we will we will explore both opportunities to do that ourselves in territories, where that is rational and also opportunities to partner with these rational where that makes sense too. We can take advantage of other people's infrastructure et cetera.
Speaker Change: Nonetheless, the most important thing is that we get the U S right and Thats really where all of our focus is internally at the moment and so.
Speaker Change: So whilst we are having.
Speaker Change: <unk> with the policies.
Speaker Change: About ex U S strategies, our focus is very clearly on the United States.
Speaker Change: Gavin do you want to talk financials, yes, thanks, Greg.
Speaker Change: With regards to financials in the earnings release today.
Speaker Change: Given the impact of the restructuring on internal teams and kind of the ecosystem.
Speaker Change: Some new areas for the board is considering including revenue and inventory.
Speaker Change: Just need a little bit of a time to finish the 10-K officer will be covering that as of Monday with regards to your forward looking questions around opex in 2025.
Speaker Change: Reiterate what we said at Q2, we think the restructuring.
We will reduce our run rate costs in Q in 2025 on a roundabout 50 million today, we've announced that we'll be pushing our preclinical programs on hold and prime to ADP.
Speaker Change: <unk> 'twenty that will drive incremental savings of roughly $75 million to $100 million over the next four years, an element of that will be in 2025, and we will be able to update you in more detail on that at the Q1 earnings call.
Speaker Change: Yes.
Speaker Change: Our next question comes from.
Xu: Xu from Wells Fargo. Please go ahead with your question.
Ya man: Hi, Thanks for taking our questions. This is quantify them for Ya man. So a question any thoughts on Iran. T cells is there a lounge and ATC. So you mentioned that the majority of patients of Gregory's is so far came from a majority of them came from the first five ATC.
Ya man: Can you remind us when did those Fi atc's beef Tam active and.
Ya man: Do you expect the additional ATC to onboard patients.
Ya man: Those five.
Ya man: A T six thank you.
Ya man: Thank you I can't I can't yes, I can address that question. So those 586 were active.
Ya man: Last year throughout the launch and we do expect now the agencies that have been activated this year to bring additional patients in fact, 85% of the <unk> of the <unk>.
Ya man: <unk> that are already in our web site have.
Ya man: I think you've had at least one patient the majority of them.
Ya man: Multiple patients and so that's going to continue to grow wisely.
Ya man: Onboarding activity more agencies.
Ya man: Got it.
Ya man: Thank you for that and can you can you remind us.
Ya man: What percentage of the patient at the first 20 Atc's cover and how about the next time. Thank you.
Ya man: So what's happening.
Ya man: Is that good.
Ya man: All right.
Ya man: Continue to happen.
Ya man: The patients can be tested anywhere.
Ya man: No.
Ya man: They are being tested locally and then when that patient is.
Speaker Change: Biomarker positive patients based on from both Biomarkers than they end up getting referred to chew. The treatment centers that are active already so its hard to calculate the number of patients for ATC because that referral pattern is being established as.
Ya man: Reactivate disease.
Ya man: Uh huh.
Ya man: Currently the.
Ya man: Proximity to the patients and the person who made it to where the referral sites or it's going to make it easier for patients to get to the treatments the treatment centers the more treatment centers we have.
Ya man: Does that answer your question.
Ya man: Yes, that's helpful.
Ya man: Thank you so much right now.
Ya man: Thank you.
Speaker Change: Our next question comes from George Farmer from Scotiabank. Please go ahead with your question.
George Farmer: Hi, good morning, Thanks for taking my questions.
George Farmer: First one is on your ex U S. Efforts. This was touched on earlier, but are you actively engaging in the process of trying to have a filing in the EU or is that on hold and.
George Farmer: You know realistically when do you think this drug could be available.
George Farmer: On the cell therapy could be available in Europe.
George Farmer: And my second question relates to.
George Farmer: Premium <unk> 70 can you talk about any level of.
Outside interest in these programs and do you think that those programs can be monetized in any way.
George Farmer: Here in the near future.
Speaker Change: Yes, hi.
George Farmer: Sorry.
George Farmer: I was gonna say, we haven't provided timelines for the for the ex U S filing et cetera, but I would like to ask Dennis to comment on.
Speaker Change: Regulatory position development position that particularly.
George Farmer: Particularly for the year.
Ed: Yes, Thanks Ed.
George Farmer: We have for.
Speaker Change: <unk>, we are part of the Prime scheme in Europe for this program.
Speaker Change: All the things that you would typically do pre approval in advance of.
Speaker Change: Marketing applications. So we have an agreed pediatric investigational plan, we have orphan drug designation.
Speaker Change: For a variety of strategic reasons to make a stronger application were more likely to go in with the full trial results meeting cohorts, one two and three.
Speaker Change: Of the spearhead one trial.
Speaker Change: So as you know right. We're looking to conclude our confirmatory evidence later this year. So we're going to report out the results of cohorts two and three in the third quarter end.
Speaker Change: When we have the totality of data.
Speaker Change: Yes.
Speaker Change: Independent of the launch activities in Europe, that's really the strategy, we would go in with our marketing applications in Europe.
Speaker Change: Vision was to pursue that.
Speaker Change: Thanks Dennis.
Speaker Change: With respect to your other question.
Speaker Change: <unk>.
Speaker Change: Don Prime and CD 70.
Speaker Change: Both of those programs target.
Uh huh.
Speaker Change: What I generally regarded in the industry is.
Speaker Change: Every high value large opportunity targets and they are worthy of interest to a range of pharma companies.
Speaker Change: And other large large and small biotech to have programs in this space.
Speaker Change:
Speaker Change: And so we could continue to build.
Speaker Change: Leave that.
Speaker Change: We have ongoing discussions.
Speaker Change: That those off guys delays are likely to be valuable programs for us. However.
Speaker Change: We'll refer to my comments in the scripted portion of this of this call.
Speaker Change: We are exploring all opportunities for it.
Speaker Change: To be able to.
Speaker Change: Enable us to be successful with our sarcoma franchise that includes those partnerships. It includes other collaborations strategic combinations finance other financial transactions and and monetization opportunities as well.
Speaker Change: And we have a lot of those levers that we can pull and we will give updates when we have.
Speaker Change: Something tangible to talk about.
Speaker Change: Okay. Thanks Adrian.
Speaker Change: Yes, Joe.
Speaker Change: Our next question comes from Arthur Heat from H C. Wainwright. Please go ahead with your question.
Speaker Change: Hey, good morning, and thanks.
Arthur Heat: Thanks for taking my question. So I apologize. If this question has been addressed before so.
Could you just give us more color on the patient number has been.
Arthur Heat: Identified by market outage books during so far during this year.
Arthur Heat: Okay.
Arthur Heat: Yes so.
Arthur Heat: Maybe I'll ask I'll ask I'll ask.
Arthur Heat: Cynthia to comment on that.
Speaker Change: Yeah I can address that we in addition to the 10 patients that has been equally we do have line of sight for about.
Speaker Change: 20, other patient centered double positive and are going to be.
Speaker Change: Getting into that journey moving forward.
Speaker Change: We see a lot of excitement from the sites with the launch and now do you have the ability of this new option for patients.
Speaker Change: It has not had any innovation so we see it.
Speaker Change: Heitman in sites, becoming treatment centers, but also with the other sarcoma centers of excellence in identifying and testing patients.
Speaker Change: Thank you.
Speaker Change: Just a quick follow up so to date.
Speaker Change: The roughly conversion rates from the double positive patients to get the F races.
Speaker Change: Thanks, Tamara a matter of time than than percentage and so each patient has very different journeys it can take different timings.
Speaker Change: Timing for them to be able to get your insurance approval schedule. It freezes and go through the process.
Speaker Change: Just two very well.
Speaker Change: Hello numbers at this time for us to be able to calculate any very specific statistics, but the majority of them are going through that journey.
Speaker Change: Overtime.
Speaker Change: Oh. Thank you very helpful. Thanks for taking my question.
Speaker Change: Thanks, Thank you.
Speaker Change: Our next question comes from Michael Kim from Zacks small cap research. Please go ahead with your question.
Michael Kim: Hey, everyone. Good morning, Thanks for taking my questions.
Michael Kim: First just curious to get your perspective on the incremental $75 million to $100 million of savings related to our <unk>.
Michael Kim: Zing on frame and CD 70, just in terms of.
Michael Kim: How these incremental savings impact.
Michael Kim: The anticipated timeline for reaching an inflection and operating profitability.
Speaker Change: Yeah. Thanks, Michael So clearly incremental savings will will help et cetera right.
Speaker Change: That time to profitability, but there are a number of other variables.
Speaker Change: Involved in that including successful launch of two seller and the acceleration of ramping.
Speaker Change: Or do you seeing that of course with four or five months into this.
Speaker Change: Let yourself be important part of that as well.
Speaker Change: There are variables, but continue to focus on our cost base and.
Speaker Change: They can just mentioned that weather katana assets to work will clearly help in expediting that then.
Speaker Change: Voyage to profitability.
Speaker Change: Got it Okay and then.
Speaker Change: I appreciate the commentary on on let us sell in terms of.
Speaker Change: Initiating the BLA later this year.
Speaker Change: With an anticipated approval in 'twenty six.
Speaker Change: Which I think would would represent a meaningfully shorter timeline with respect to the process for to salaries. So just curious to get your thoughts on where you you might be able to leverage your experience with to sell red to drive.
Speaker Change: Synergies or efficiencies and then what's what sort of timeline are you are you building in for <unk>.
Speaker Change: D. A approval once you complete the BLA.
Speaker Change: Sure.
Speaker Change: Okay.
Speaker Change: Thanks, Rocco I'm going to ask Dennis to talk about the.
Speaker Change: The how the learnings from T cell have built into our plans for four left to sell in the path to approval and then maybe I'll ask Cynthia to talk about how we anticipate the launch of <unk> of left to sell in the context of a fully established commercial organization and.
Speaker Change: Network that we've established with T cell right Dennis do you want to go for.
Speaker Change: Yes.
Speaker Change: Yeah sure. Thanks, Ed.
Speaker Change: There are a lot of learnings that we have from the.
Speaker Change: <unk> cel BLA review and approvals that we have already incorporated into the planning of.
Speaker Change: The let us sell BLA.
Speaker Change: Prepare it so they can be on the clinical side, just the CMC side think that the FCA going through that process with essentially the same patient population.
Speaker Change: That they would expect to see.
Speaker Change: As far as planning around that.
Speaker Change: <unk> diagnostics and having contemporaneous approval. So all of those learnings will be applied now to your question about the FDA review period.
Speaker Change: We have.
Speaker Change: Breakthrough therapy designation for both indications.
Speaker Change: Well, let us sell both for synovial sarcoma and more recently that we received for Myxoid round saw length of sarcoma.
Speaker Change: That application that breakthrough therapy designation was based on the results of the ignite yourself right. So the FDA is where you see some of the data from the pivotal trial.
Speaker Change: But.
Speaker Change: These designations grant a lot of.
Speaker Change: Avenues to expedite development among them is the Rolling review, which we intend to pursue that and we will start that process at the end of the year.
We would also be eligible for a priority review and a priority review for this application would essentially be eight months. So this is some of the timings that go into the plan, where we would expect approval at the end of next year.
Speaker Change: And then Cynthia I think youre going to have some additional comments about our launch activities.
Cynthia: Yes, Thank you Dennis.
Cynthia: So from a commercial perspective as you would imagine there's a lot of synergies.
Cynthia: So initially hardwood.
Cynthia: Therapy Echo my something new so casting patience is something that is being established right now for <unk>.
Speaker Change: Alright, and Thats going to be established when we bring latest come on board is going to be a different target, but the paradigm of test locations for sarcoma is gonna be established.
Cynthia: <unk> seen that work.
Cynthia: Going to be available and a lot easier to just pick up on I'm glad to sell commercial platform.
Cynthia: In place in terms of ordering and all of the chain of custody channel I think you could process. It is always published already.
Cynthia: And we do have a small commercial team, but really we're very proud of them.
Cynthia: The team that is in the field across both medical and commercial they're very experienced in working with the sites and the customer overlap with <unk>.
Cynthia: 100%. So we're gonna allows it's exactly the same.
Cynthia: Network, and and commercial footprint medical footprint that we have in place at this time, so a lot of synergies with lead itself.
Speaker Change: Great very helpful. Thanks for taking my questions.
Mark: Thanks, Mark Thank you.
Mark: Once again, if you would like to ask a question. Please press star and then one to withdraw your question you May press Star and two.
Speaker Change: Our next question comes from Peter Lawson from Barclays. Please go ahead with your question.
Peter Lawson: Alright, thanks for the update.
Peter Lawson: Just on the <unk> sort of actively infused in patients.
Peter Lawson: How many are infused more than one patient.
Peter Lawson: What percentage of those Atc's right actively infusing and then just your confidence level of rents.
Peter Lawson: Whether it's meeting or exceeding that target.
Peter Lawson: Sensors by year end.
Peter Lawson: Cynthia.
Peter Lawson: I can address that so the.
Peter Lawson: Yes.
Peter Lawson: As I mentioned before about 580 fees has been the ones who are responsible for the patients that have been trained so far we do have to see that introduced more than one patient.
Peter Lawson: And the pace in rights fees are.
Peter Lawson: Enrolling patients and.
Peter Lawson: Having patients with freezing.
Speaker Change: Exactly as what we would expect the pace of Onboarding Atc's has actually been a little faster than what we expected based on prior experiences.
Speaker Change: And I attribute that really to the excitement of the sarcoma specialists to be able to offer this new treatment.
Speaker Change: Treatment option for their patients.
Speaker Change: And also the fact, we learned a lot from the.
Speaker Change: The prior cell therapy programs, we had a lot of conversations with.
Speaker Change: Our treatment centers to make sure that we implemented and Onboarding process that was as simple as it could possibly be.
Speaker Change: And having a team that is a very focused and customized Q.
Speaker Change: And meet the needs of these customers in a way that at the processes as simple as it can be and it can be expedited and we can troubleshoot very specifically as needed.
Speaker Change: Great. Thank you and then are there any capacity constraints among other factors bottlenecks that could potentially limit.
Speaker Change: The patient infusions, you need to kind of hit to 2020 fives.
Speaker Change: And also that 2020.
Speaker Change: Profitability number.
Speaker Change: We have not seen any capacity limitations, so far not on our manufacturing side not on the site side as well in terms of at Asa Eases bad and.
Speaker Change: Maybe John can comment on this as well.
Speaker Change: Our capacity is enough to reach all of our both.
Speaker Change: John you want to comment on it.
John: Sure. Thanks Sanjay.
Sanjay: Absolutely I think some of the challenges that we have perhaps seen many other car T launches that we've learned from them put us in a position where we don't have capacity constraints Adrian mentioned that we've been exceeding our targets of the 30 day time from the Hay freezes collection to release.
Sanjay: And he also mentioned and while it's a small number we've had 100% success rate thus far with our commercial which is of course both of those are different than what you've seen in other car T. So it just gives us continued confidence that we've set this up right for a successful launch in <unk>.
Sanjay: Ultimately all the way to let us sell as well.
Sanjay: Thank you.
Speaker Change: Hard to.
Speaker Change: Kind of break out individual components, so that cost savings from train CD 70, and headcount reduction what proportion of that is kind of folded into the commercial rollout for us has extended the cash runway.
Kevin: Okay Kevin.
Peter Lawson: Yes, Peter I think you rightly say, it's difficult to break those competitors.
Peter Lawson: At the moment will certainly give a further update to the Q1 earnings update.
Peter Lawson: But we are we are absolutely focused on successful commercial launch and.
Peter Lawson: And deploying resources appropriately to support what's been said for a very successful launch et cetera.
Speaker Change: Alright. Thank you so much good luck imports.
Peter Lawson: Thanks Peter.
Speaker Change: And ladies and gentlemen, with that we'll be concluding today's question and answer session I'd like to turn the floor back over to Adrian uplift for closing remarks.
Adrian Uplift: Thanks, and thank you everybody for your questions as I think we've demonstrated we have great traction and acceleration on the launch of T sour and I'm really looking forward to being able to update you on our bias as we move through the year and also on the progress towards the BLA for four let yourself.
Adrian Uplift: We will continue to manage the cost base, we will continue to push forward through to profitability in 2027.
Adrian Uplift: And we will leave no stone unturned to enable us to achieve that.
Adrian Uplift: From a financing perspective.
Adrian Uplift: And with that ill close the call. Thank you for your questions and your interest.
Speaker Change: This brings to a close today's conference call. You may disconnect. Your lines. Thank you for participating and have a pleasant day.
Speaker Change: [music].